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The technology of fabricating microneedle arrays to deliver high molecular weight drugs 
across skin in a minimally invasive manner is receiving increasing attention. Microneedle 
arrays with different geometries have been manufactured using materials such as glass, 
polymer, metal, etc. However, a framework that can identify the optimum designs of these 20 
arrays seems to be lacking. This is important since by optimising the microneedles 
dimensions (e.g., surface area of the patch, microneedle radius, etc) the permeability of 
drugs in skin can be increased. To address this issue, this study presents an optimization 
framework for transdermal delivery of high molecular weight drug from microneedle. The 
optimization process is based on determining an optimisation function (g) for various 25 
microneedles patterns (e.g., square, diamond, triangular, etc). We argue that higher the 
value of g is the higher the drug permeability in skin is. The outputs of the developed 
framework have allowed us to identify the optimum design of both solid and hollow 
microneedles. In particular, the results have been used to predict skin permeability of high 
molecular weight using microneedle system. Also, optimum designs based on different 30 
classifications of skin thickness (e.g., race, age, etc) for transdermal delivery of drugs are 
suggested. 
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1. Introduction 
For many years it has been seen that a variety of drugs can be successfully administered 
through transdermal drug delivery. For example, applications involving delivery of 40 
nitroglycerine ointment (Henzl and Loomba, 2003) and nicotine patch (Edelman, 2001) 
have proven the viability of such transdermal drug delivery systems. However, the range of 
drugs that are incorporated into the drug delivery systems is often restricted by the barrier 
function of the skin. The outer layer, or the stratum corneum, is the main obstacle to 
transdermal drug delivery when a drug diffuses through the skin (Sivamani et al., 2005). 45 
One of main aims in transdermal drug delivery research is to increase the permeability of 
drug penetrating the skin (Al-Qallaf and Das, 2008a,b). This is because skin permeability is 
a key parameter that represents the path length of a molecule across a given skin thickness 
over unit time (Environmental Protection Agency, 1992). One way to resolve these  issues 
is to employ microneedle arrays as a transdermal delivery system (Lee et al., 2008). They 50 
consist of micron-sized projections that pierce the stratum corneum allowing the drugs to 
bypass the main barrier to diffusion. Studies have shown that the microneedle arrays cause 
no or little pain and are well tolerated by users, making it preferential to injection by 
syringe (Nir et al., 2003; Prausnitz et al., 2005; Simonsen et al., 1999). The microneedles 
can also offer a number of other benefits over other drug delivery methods. For example, 55 
many drugs administered via an oral route may be susceptible to poor absorption (Stoeber 
and Liepmann, 2000) and hence have a low bioavailability (Cross and Roberts, 2004). This 
is not the case when using microneedles where the drugs only diffuse over a short distance 
before reaching the blood circulation which enhances the absorption of drugs by the tissue 
(Aziz and Majlis, 2006; Aggarwal and Johnston, 2004). 60 
 
The concept behind microneedles was suggested in the 1970’s but it was not until the 
1990’s that their utility was demonstrated experimentally (Roxhed et al., 2007). This was 
mainly thanks to the advances in the microelectronics industry that allowed the production 
of micron-scale structures. The first needles to be reported in literature were created by 65
Hashmi et al. (1995) to increase molecular and genetic material uptake in cells. The first 
study to determine whether microneedles could be used to increase skin permeability was 
conducted by Henry et al. (1998). They found that the skin permeability to calcein (a model 
drug) could be increased by over 3 orders of magnitude in vitro. Microneedles have been 
shown to deliver high molecular weight drugs, DNA, proteins and vaccine (Lee et al., 2008; 70 
Pearton et al., 2007; Reed and Lye, 2004). In addition to this, it was found that the use of 
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microneedles is painless and does not damage the tissue as the short micro-projections were 
not long enough to stimulate the nerve endings in the deeper tissue of the skin (Jiang et al., 
2007; McAllister et al., 2000). Since these promising early results, developing 
microneedles suitable for pharmaceutical applications has been an active area of research. 75 
 
It is also interesting to note that since the first fabrication of these microneedles, a variety of 
designs involving different distributions of the microneedles have been proposed. However, 
studies aimed at optimizing the dimensions of these microneedles have been limited. An 
approach to determine the optimal shape of microneedle by maximizing the buckling load 80 
has been presented by Vasquez and Pelesko (2005). A method to optimize the hole 
locations of various microneedle has been proposed by Khumpuang et al. (2007). 
 
Recently, we have initiated investigations on optimizing the square patch of microneedle 
arrays (Al-Qallaf and Das, 2008a,b). They have been done by considering the microneedle 85 
dimensions (e.g., number of microneedles, microneedle radius, etc) of both solid and 
hollow microneedles to maximize the drug skin permeability. However, it is realized that 
since the first fabrication of microneedles a large variety of microneedle distribution have 
been proposed such as square (Ji et al., 2006; Kim and Lee, 2007), hexagonal (Matriano et 
al., 2002; Widera et al., 2006), triangular (Perennes et al., 2006) and rectangular (Park et 9 
al., 2005). Aggarwal and Johnston (2004) investigated the influence of various patterns 
(e.g., square, rectangular, etc) on buckling force, bending force and bending stress. Our 
previous work (Al-Qallaf and Das, 2008a,b) have attempted to study and hence optimize  
the square patch with a square microneedle distribution to maximize the skin permeability. 
While the developed framework (Al-Qallaf and Das, 2008a,b) is useful, it seems it is also 95 
necessary to develop the wider applications of the framework to non-square distributions of 
the patterns so as to optimize them for transdermal drug delivery. To address this issue, we 
extend our previous work (Al-Qallaf and Das, 2008a,b) to consider non-square patterns 
(i.e., rectangular) as well as the distribution of microneedles such as triangular and 
diamond. We optimize and compare the microneedle arrays of both square and rectangular 100 
patch to maximize skin permeability of both solid and hollow microneedles. The 
optimization framework of considering both the microneedle pattern as well as the 
distributions allows us to identify the optimum pattern and distribution to enhance the 
performance of microneedles array. It must be pointed out that in the present context 
‘pattern’ means the shape of the microneedles array (i.e., square or rectangular) and 105 
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‘distribution’ means the arrangement of the microneedles inside an array (i.e., triangular or 
diamond). 
 
In this work, we have also considered the epidermis thickness of various skin thickness 
classifications (e.g., race, sex, etc). In another case, the microneedle length has been 110 
considered to evaluate the skin permeability of the optimum models proposed. The 
outcomes of this work have allowed us to predict and hence relate skin permeability with 
the diffusion coefficient of various model drugs. The hexagonal pattern is not considered in 
this paper as we have previously showed that the effective skin permeability is only slightly 
higher in the hexagonal pattern than the square pattern (Davidson et al., 2008). This means 115 
that there is not much difference between the square and the hexagonal patterns and the 
square pattern has almost the same influence as the hexagonal pattern. 
 
2.  Methodology  
2.1 Theoretical Model 120 
To develop the current framework, a simple theoretical in vitro model was adopted using 
the following equation to calculate skin permeability when using microneedles (McAllister 
et al., 2003): 
hL
DfK =                     (1) 
Here, K is the skin permeability of drugs, f is the fractional skin area after insertion by 125 
microneedles, D is the effective diffusion coefficient of drugs in skin and Lh is the length of 
a hole in skin. The hole length (Lh) represents either the epidermis thickness (h) in case of 
solid microneedles or the microneedle length (L) in case of hollow microneedles. This 
depends on the movement of drug molecules. In the case of solid microneedles the drug 
molecules do not move through the microneedle itself but traverse through various 130 
disruptions in the skin thickness (i.e. epidermis) from the patch to blood vessels. In the case 
of hollow microneedles, the molecules move through the bores of hollow microneedle and 
this path length represents the microneedle length. The assumptions of this developed 
framework have been explained in detail previously (Al-Qallaf and Das, 2008a). 
 135 
The fractional skin area in equation (1) when the microneedles are inserted in skin is given 
as: 
 5 
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Here, Nt is the total number of microneedles for a given patch, R is the microneedle radius, 
W is the annular gap width (W) and A is the surface area of the patch. We have adopted 140 
equation (2) as our main governing equation for the optimization framework to maximize 
the skin permeability in equation (1). 
 
The annular gap width (W) is defined as a function of microneedle radius (R) as follows: 
RW ε=                     (3) 145 
Here, ε  is a dimensionless parameter for the ratio of annular gap width over microneedle 
radius. 
 
2.2 Formulation of Optimization Function 
In our previous study (Al-Qallaf and Das, 2008a,b), we have defined that the microneedles 150
array has a square patch, where the total number of microneedles (Nt) is n by n (the number 
of microneedles per row). For the purpose of this work, we substitute equation (3) into (2) 
and rearrange as follows: 
)2(
A
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2
t +εεπ=                      (4) 
Also, combining equations (1) and (4), the skin permeability for the cases when 155 
microneedles are inserted is: 
h
2
t
L
D
A
RN
cK π=                    (5) 
Here, )2(c +εε=                    (6) 
As Lh, D, c and π are constants, the problem statement in equation (5) can be reformulated 
as: 160 
A
Rng
22
=                     (7) 
Where g is the optimization function derived and n2 is the total number of microneedles 
provided that the total number of microneedles (Nt) equals n × n as explained before. 
Therefore, the skin permeability when microneedles are inserted can be introduced as: 
hL
DgcK π=                     (8) 165 
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Therefore, the skin permeability (K) in equation (5) increases by maximizing the 
optimization function (g) in equation (7) such that: 
maxmin nnn ≤≤                  (9a) 
maxmin RRR ≤≤                  (9b) 
maxmin AAA ≤≤                  (9c) 170 
It is obvious from equation (7) that g reaches its highest value for maximum values of n and 
R and, minimum A. However, we have showed previously the importance of introducing a 
new constraint as follows (Al-Qallaf and Das, 2008a,b): 
RPt α≥                   (10) 
Here, Pt is the pitch, the distance of centre-to-centre between two adjacent microneedles as 175 
shown in Fig. 1 and, α  is the aspect ratio of the pitch over microneedle radius so that 
0.2>α  to prevent any overlapping between two adjacent microneedles. We define the 
pitch as (Al-Qallaf and Das, 2008a,b): 
n
APt =                   (11) 
Equations (10) and (11) are combined to yield a new constraint for optimisation as (Al-180 
Qallaf and Das, 2008a,b): 
R
n
A
α≥                   (12) 
 
To further study the case of square patch, we investigated the influence of changing the 
pattern by introducing the diamond and triangular patterns as shown in Fig.1. The idea of 185 
the microneedles distribution is analogous to the packing of tubes in heat exchangers, 
where the tubes in the heat exchangers represent the microneedles (Hewitt, 1990; Perry et 
al., 1984). 
 
The pitch of the diamond pattern per row (Ptn) or per column (Ptm) is given as follows: 190 
ttmtn P707.0PP ×==                 (13) 
Therefore, the area of a square array for the diamond pattern is: 
tmtn Pm2Pn2A ×××=                 (14) 
 7 
Here, m is the total number of microneedles per column and assuming n equals m since the 
patch has a square shape. By combing equations (10), (13) and (14), the new constraint of 195 
the diamond pattern is: 
R
mn414.1
A
α≥
××
                 (15) 
Although n equals m and Ptn equals Ptm, the ranges of both Ptn and Ptm are different 
according to the reported values in the literatures. Therefore, we define the total number of 
microneedles and pitch per either row or column as n and m so that the optimisation 200 
program can iterate the input parameters depending on the selected range for n and m. 
 
In case of the triangular pattern, the pitch for each per row (Ptn) is given as follows: 
ttn P866.0P ×=                (16a) 
On the other hand, the pitch of the triangular pattern for each column (Ptm) is given as 205 
follows: 
ttm P5.0P ×=                 (16b) 
By combing equations (10), (14), (16a) and (16b) we find that the area of a square patch for 
both the triangular and diamond patterns is equal. Therefore, the new constraint of 
triangular pattern is: 210 
R
mn316.1
A
α≥
××
                 (17) 
 
To expand the scope of this work further, we have included the rectangular patch as shown 
in Fig. 1. The optimization function (g) of this patch can be introduced as: 
A
R)mn(g
2×
=                  (18) 215 
Here, n is not necessarily equal to m. The area of a rectangular patch is: 
tmtn PmPnA ×××=                  (19) 
Hence, the new constraints for the rectangular patch are given as: 
R
Pmn
A
tn
α≥
××
                 (20) 
R
Pmn
A
tm
α≥
××
                 (21) 220 
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Therefore, the optimization function (g) in equation (18) is maximized by considering the 
constraint equations (9a-9c) along with the following constraint: 
maxmin mmm ≤≤                (22a) 
maxtntnmintn
PPP ≤≤               (22b) 
maxtmtmmintm
PPP ≤≤               (22c) 225 
The values of microneedle pitch (Ptn) and (Ptm) for all patterns are explained in Table 1. 
 
2.3 Method of solution 
In this work, an in-house java program is used to solve the optimization equations (7) and 
(18) for the constraint equations (9a-c), (12), (15), (17) and (20-22c). The input parameters 230 
for solving these equations are as shown in Table 2 which are mostly adopted from reported 
literature. In some cases, we have expanded the microneedle geometries to cover a broader 
range of parameters. For example, nmax of rectangular patch has been increased to 20 for 
both solid and hollow microneedles and, also the aspect ratios (α) of square, diamond and 
triangular patterns of solid microneedles have been extended to 20 as compared to the 235 
reported values. On the other hand, the aspect ratios of hollow microneedle for diamond 
and triangular patterns have been increased to 30 and for square and rectangular patterns to 
40. The inconsistency of this expansion is due to the unfulfillment of the geometrical 
condition of this optimization model. For briefness, the description of the developed 
framework of the optimization algorithm is avoided as it was explained previously (Al-240 
Qallaf and Das, 2008a,b). It must be added, however, that for a given iteration of the 
optimisation algorithm, a scale (step size) is defined by the user for each parameter as 
shown in Table 2. 
 
3. Results and Discussions 245
Some typical results of the developed optimization model for the input parameters (Table 
2) for both solid and hollow microneedles are listed in Table 3. As stated before, our 
approach of optimization involves developing a method to maximize the skin permeability 
to obtain optimum microneedle design of various patterns with different geometries for 
solid and hollow microneedles. Therefore, the purpose of these simulations is to identify 250 
both the optimum pattern and distribution of microneedles to enhance the performance of 
microneedles array. The results presented in Table 3 show that in case of solid and hollow 
microneedles, the maximum values the optimization function (g) are approximately 0.081 
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and 0.13, respectively. As discussed below, various microneedle patterns and their 
geometries (e.g., number of microneedles per row, microneedle radius, etc) have been 255 
optimized and analysed to address their influences in terms of the optimization function (g), 
and thereby, the design of microneedle. The outcome of the simulations allow us to identify 
the optimum dimensions of microneedles by reaching the highest values of the optimization 
function (g). These optimum dimensions are then used in equation (8) to determine the 
optimums skin permeability. This is done by either varying the classification of skin 260 
thickness in case of solid microneedles or microneedle length in case of hollow 
microneedles. Moreover, the optimum dimensions of both solid and hollow microneedles 
are correlated with the diffusion coefficient to predict various correlations for different 
microneedles shapes and patterns. The issues related to predicting drug concentration in 
blood will be discussed in a future paper.  265 
 
3.1 Optimization of Surface Area of Patch 
The design of microneedle arrays is constrained by a number of parameters including the 
surface area of microneedle arrays (Gill and Prausnitz, 2007; Al-Qallaf and Das, 2008a,b; 
Al-Qallaf et al., 2007). For the purpose of this section, we studied the surface area of 270 
microneedle arrays with a view to optimize this parameter and hence, enhance the drug 
delivery process. As shown in equations (7) and (18), there is an inverse relationship 
between the surface areas of square and rectangular patch and, the optimization function 
(g). We have carried our simulations to present the influence of this inverse relationship for 
different microneedle patterns for both solid and hollow microneedles (Fig. 2). Based on 275 
the optimum results listed in Table 3, our optimization approach suggests that the best 
microneedle pattern for solid microneedle is either the square or the rectangular patch 
corresponding to an optimization function (g) of 0.081 and a surface area of 0.15 cm2 and 
0.49 cm2, respectively. On the other hand, the best microneedle pattern for hollow 
microneedle is the rectangular pattern corresponding to an optimization function (g) of 0.13 280 
and a surface area of 0.18 cm2. The simulations show that the rectangular patterns of both 
solid and hollow microneedles give the highest values of optimization function (g) and 
hence, higher skin permeability. The general practical implications of these results, e.g., the 
suitable patterns for a given scenario (e.g., skin thickness), are discussed in the following 
sections. 285 
 
3.2 Optimization of Microneedle Radius 
 10 
The implications of studying the influence of the proportional relationship between the 
optimization function (g) and microneedle radius as shown in equations (7) and (18) are 
illustrated in this section. Figure 3 shows the dependence of the optimization function (g) 290 
on the microneedles radius (R) of both solid and hollow microneedles for the tested patterns 
with corresponding optimum surface area of microneedle array as listed in Table 3. We 
define the optimum value when the highest value of g function is reached. This is because 
we are seeking the maximum skin permeability and hence, the maximum values of g 
function. Among the microneedle pattern evaluated, the highest and lowest optimum values 295 
of the microneedle radius in case of solid microneedles are 0.01 cm and 0.0055 cm for 
rectangular and diamond patterns, respectively (Fig. 3). Moreover, the highest and the 
lowest optimum values of the microneedle radii in case of hollow microneedles are 0.0135 
cm and 0.0115 cm for square and triangular patterns, respectively. Our results suggest that 
optimizing microneedle radius to maximize the optimization function (g) is valuable for 300 
enhancing the optimized skin permeability (K). These results agreed well with a previous 
experimental result presented by Teo et al. (2005). 
 
3.3 Optimization of the number of microneedles per row 
The influence of the number of microneedles on the performance of the microneedles array 305 
has been addressed previously (Park et al., 2005; Stoeber and Liepmann, 2005). 
Nevertheless, we believe that it is also necessary to consider how to optimize the total 
number of microneedles (Nt) in a given patch for a given pattern. The implications of 
changing the optimum number of microneedles of both per row (n) and per column (m) on 
the optimization function (g) for various microneedle patterns is shown in Fig. 4. It must be 310 
pointed out that the total number of microneedles in Fig. 4 are explained in Table 4 for 
clarification. The optimization function for both solid and hollow microneedles varies 
almost linearly with the total number of microneedles for all cases of microneedle patterns.  
The results in Fig. 4 indicate that the highest optimization function in terms of solid 
microneedles happens for either the square or rectangular patterns, whereas, in terms of 315 
hollow microneedles it happens for the rectangular pattern. The optimum designs may offer 
variety of benefits for designing microneedle geometries for a given purpose, e.g., reducing 
the cost of fabrication, etc.  
 
3.4  Optimization of the Aspect Ratio (α) 320 
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In this work, the aspect ratio (α) is defined as the ratio of the center-to-center distance 
between two microneedles (pitch) to the microneedle radius (R). In general, this parameter 
should be greater than 2.0 so that an overlapping between any two microneedles does not 
occur. Further, if the pitch is too small (<2.0), then the needles are placed too close to one 
another which may prevent them from pain free penetration of the skin due to their 325 
mechanical strengths and reaching the targeted depth (Miyano et al., 2005). Fig. 5 
illustrates the optimum pitch (Pt) as a function of aspect ratio (α) for both solid and hollow 
microneedles of various microneedle patterns. Fig. 5 depicts that in case of rectangular 
pattern for both solid and hollow microneedles, the aspect ratio has no obvious influence on 
the optimum pitch. This means that the optimum pitch occurs at the minimum pitch of 330 
either per row (Ptn) or per column (Ptm). On the other hand, in case of other pattern, the 
optimum pitch for both solid and hollow microneedles varies nonlinearly with the aspect 
ratio. Moreover, the triangular and diamond patterns of solid and hollow microneedles, 
respectively, show partially different behaviour than the other patterns types as the highest 
optimum pitch does not occur at the highest aspect ratio. This is clear from Fig. 5 as the 335 
highest optimum pitch for the triangular and diamond patterns of solid and hollow 
microneedles occurs at an aspect value of 12 and 25 instead of 20 and 30, respectively. Fig. 
6 reveals how the aspect ratio of solid and hollow microneedles of various microneedle 
patterns influences the optimization function. As shown in Fig. 6, there is an inverse 
relationship between the optimization function and the aspect ratio for all cases of 340 
microneedles patterns for both solid and hollow microneedles except in case of rectangular 
pattern of solid microneedles. Therefore, for a given microneedle pattern (i.e., rectangular 
pattern), changing the aspect ratio does not affect the optimization function significantly. 
Moreover, the optimization function reaches its highest values at the minimum aspect ratio 
for all microneedle patters. 345 
  
3.5 Effect of the Skin Thickness 
As well known, there is strong evidence that the skin thickness can vary according to age, 
race, anatomical region and sex (Lee and Hwang, 2002; Fenske and Lober, 1986). Skin 
thickness therefore can play an important role as a barrier against any injected drugs. In a 350 
previous work, we have studied the influence of epidermis thickness of various anatomical 
regions (Al-Qallaf and Das, 2008a; Al-Qallaf et al., 2007), sex (Al-Qallaf and Das, 2008a), 
age group and race (Al-Qallaf and Das, 2008b) on skin permeability for various drugs of 
the square patch. In this work, we evaluate the effects of epidermis thickness for all skin 
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thickness classifications on drug permeation in skin of various patterns. As explained 355 
previously, the path length of skin disruption made by solid microneedles represents the 
effective diffusion length (i.e., thickness of the epidermis) and there is an inverse 
relationship between the epidermis thickness (h) and skin permeability (K) as shown in 
equation (1). The dependency of the thickness of epidermis (h) for various age groups (Artz 
et al., 1979) on skin permeability (K) for calcein as a model drug is shown in Fig. 7. The 360 
importance of considering the calcein as a model drug is avoided in this work as it was 
explained previously (Al-Qallaf and Das, 2008a). As shown in Fig. 7, there is a significant 
increase in the optimized skin permeability for either square or rectangular patterns as 
compared to the other microneedle patterns. For example, the difference in the optimized 
skin permeability for a given microneedle pattern between the epidermis thickness of age 365 
group (0-5) and age group (11-15) proves the necessity of considering the skin thickness. 
Fig. 8 shows the effect of the epidermis thickness of different races (i.e., Korean and 
Caucasian) on the optimized skin permeability for various microneedle patterns. The square 
or rectangular pattern shows significant increase when compared with the other 
microneedle patterns for a given race. In all cases of microneedle patterns, the optimized 370 
skin permeability of Caucasian race increases approximately 3 times more than Korean 
race. The evaluations of the optimized skin permeability as a function of skin thickness 
with respect to various anatomical regions are shown in Fig. 9. Also, in these evaluations, 
the optimized skin permeability is higher in either square or rectangular pattern than both 
the diamond and triangular patterns. Further, for a given microneedle pattern the optimized 375 
skin permeability is higher in abdomen as compared to back of leg. Fig. 10 presents the 
implications of changing the skin thickness in terms of sex group for various microneedle 
patterns. As expected, the optimized skin permeability reaches its highest value at either the 
square or rectangular pattern for both sex (i.e., female and male). Also, for a given 
microneedle pattern the optimized skin permeability is higher in female than male. These 380 
results justified our claim of considering the classification of skin thickness when designing 
microneedle arrays as well as when fabricating a given microneedle pattern. 
 
3.6 Effect of the microneedle length 
As explained previously, the hole length (Lh) represents the length of microneedle arrays in 385 
case of hollow microneedles. Also, the inverse relationship between the microneedle length 
(L) and skin permeability as shown in equation (1) motivated us to investigate this 
parameter as discussed below. To address this point, the influence of this parameter has 
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been investigated for various microneedle patterns on the optimized skin permeability for 
hollow microneedle arrays. As shown in Fig. 11 different dimensions of microneedle 390 
lengths have been compared. As expected, the lower the microneedle length is, the higher 
the optimized skin permeability across epidermis is. As opposed to the case of solid 
microneedles, the optimized skin permeability for a given microneedle length reaches its 
highest value in the rectangular pattern only. The observations of the simulations carried 
out indicate that the optimized skin permeability reaches its lowest value in the diamond 395 
pattern for both cases, solid and hollow microneedles. The result illustrates that the 
optimized skin permeability is a function of microneedle length and epidermis thickness in 
hollow and solid microneedle arrays, respectively and hence the necessity of considering 
these parameters for the fabrication of microneedle arrays. 
 400 
3.7 Effect of Skin Permeability 
The optimum microneedles in case of solid microneedles in Table 3 were investigated for 
different model drugs (McAllister et al., 2003). This investigation is particularly useful to 
compare the optimized skin permeability of the developed framework presented with 
respects to various microneedle patterns. Fig. 12 reflects the influences of four 405 
microneedles patterns for various model drugs on the optimized skin permeability after 
applying optimised microneedle systems (solid microneedles). As expected, skin 
permeability dramatically decreases as the diffusion coefficient of the model drugs 
decreases. The results also show that skin permeability reaches its highest value when 
calcein is delivered. This is obviously expected because calcein has the highest diffusion 410 
coefficient ( s/cm106 26−× ) (McAllister et al., 2003) among the model drugs and the lowest 
molecular weight (623 Da) (Nishimura and Lemasters, 2001). Moreover, the influence of 
various microneedle patterns for these model drugs on the optimized skin permeability after 
applying optimized microneedle system (hollow microneedles) is presented in Fig. 13. 
Also, in these measurements, the optimized skin permeability decreases by decreasing the 415 
diffusion coefficient of the model drugs. The results in both Fig. 12 and Fig. 13 suggest that 
the microneedle pattern is an important parameter to consider for optimizing and hence, 
enhancing the transdermal drug delivery using microneedles. Another aim of this work is to 
formulate a relationship between the optimized skin permeability and diffusion coefficient 
of the proposed model drugs with various microneedle models. This attempt is presented in 420
Fig. 14 and Fig. 15 for the case of solid and hollow microneedles, respectively. As shown 
 14 
in both figures, it seems there is a linear relationship in all microneedle patterns. These 
correlations are listed in Table 5 for all microneedles patterns types corresponding to their 
optimum geometries in Table 3. It must be pointed out that these correlations are valid for a 
diffusion coefficient ranges as 68 105D105.6 −− ×≤≤×  cm2/s. 425 
 
4. Conclusion 
In this study, we have extended an existing optimization approach (Al-Qallaf and Das, 
2008a,b) to optimize the pattern and the distribution of microneedles in the patch. In 
specific, we have focused on optimizing the square, diamond, triangular and rectangular 430 
distributions of microneedles with a view to optimize their design to maximize the skin 
permeability for transdermal drug delivery using microneedles. The key results of this 
paper are that it provides optimum distributions of solid and hollow microneedles with 
various dimensions of microneedle patterns. The variation of microneedle geometries (e.g., 
total number of microneedles, microneedle radius, pitch, etc) of the optimum design allows 435 
one to choose dimensions according to one's need. The results presented in this paper 
suggest that by reducing the aspect ratio, the skin permeability of drugs can be increased. 
The simulations carried out indicate that the optimized skin permeability reaches its highest 
value by adopting the rectangular pattern for both solid and hollow microneedles. 
Moreover, the optimization microneedle framework introduced here has been applied to 440 
study the influence of skin thickness with its classifications (i.e., age anatomical regions, 
etc) on the optimized skin permeability. We have shown that the skin thickness is major 
factor that must be considered in designing microneedles (i.e., microneedle patch, 
microneedle pattern). Altogether, the outcome of this work suggests that for designing 
microneedle arrays, optimizing various transport parameters as well as physical dimensions 445 
of the system enhance efficiency of transdermal drug delivery techniques. The correlations 
found in this work for the relationship between the diffusion coefficient and the optimized 
skin permeability for various microneedle patterns of both solid and hollow microneedles 
would enable prediction of drug permeation across human skin to deliver low/high 
molecular weight drug using microneedles. The optimization strategy introduced in this 450 
work could be potentially adopted for medical/clinical applications such as reducing needle 
radius to exclude bacteria and other foreign particles (Meidan and Michniak, 2004). 
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Table 1. The values of microneedle pitch for various patterns and types. Here, ‘pattern’ 
means the distribution of the microneedles inside an array and ‘type’ means the shape of the 
pattern. 
  655 
 
 
 
 
 660 
0.5Ptn 0.707Pt
 
Pty Pt Ptm 
0.866Pt
 
0.707Pt
 
Ptx Pt 
 
Ptn 
30ο 45ο 90ο 90ο θPt 
Triangular Diamond Rectangular Type 
Pattern
  
Ptn=Pt 
Ptn 
θPt θPt Ptm= Pty 
Ptx 
Ptn 
= 
θPt 
Pt 
Ptn 
Ptm 
Pt 
Ptm 
Ptn 
Pt 
Pt 
Square 
 22 
Table 2. The input geometrical parameters used in this work for optimizing solid and 
hollow microneedles arrays  
 
n: number of microneedles per row; m: number of microneedles per column; R: 665
microneedle radius; A: surface area of microneedles array; α: the aspect ratio of pitch over 
radius; Ptn: the pitch in x direction, the distance between two adjacent microneedles per row 
and Ptm: the pitch in y direction, the distance between two adjacent microneedles per 
column. 
AKaushik et al. (2001), BShikida et al. (2006), CPark et al. (2005), DTeo et al. (2005), EXie 670 
et al. (2005), FWu et al. (2007), GKhumpuang et al. (2007), HVerbaan et al. (2007), IChoi et 
al. (2006), JHan et al. (2007), KMiyano et al. (2005), LMartanto et al. (2004), MKhumpuang 
et al. (2006) and NPark et al. (2007). 
 
 675 
  
 Rectangular 
Pattern 
Square/Diamond/Triangular 
Pattern 
Parameters Solid Hollow Solid Hollow Scaling 
Parameters 
N 10D≤n≤20E 4H≤n≤20A 3I≤n≤10C 4M≤n≤10N 1 
M - - 4I≤n≤20C 8M≤n≤20N 1 
R 0.0025B≤R≤0.0075D 0.004A≤R≤0.015G 0.005J≤R≤0.01K 0.005M≤R≤0.0125N 0.0005 
A 0.04D≤A≤0.81C 0.04D≤A≤0.56F 0.03K≤A≤1.6L 0.02M≤A≤0.64N 0.01 
Α 2.7D≤α≤12C 3.1A≤α≤25F 3.5K≤α≤40J 3.2N≤α≤16N - 
Ptn - - 0.035K≤Ptn≤0.2J 0.03M≤Ptn≤0.04N 0.001 
Ptm - - 0.035K≤Ptm≤0.2J 0.03M≤Ptn≤0.08N 0.001 
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Table 3. The optimum parameters found using the developed framework for both 
solid and hollow microneedles for various patterns.   
  Solid Microneedles Hollow Microneedles 
Pattern Array R A g Array R A g 
Square 1717×  0.0065 0.15 0.081 1515×  0.0135 0.42 0.098 
Diamond 1616×  0.0055 0.19 0.41 1111×  0.011 0.3 0.049 
Triangular 1212×  0.006 0.11 0.047 99×  0.0115 0.19 0.056 
Rectangular 2020×  0.01 0.49 0.081 1510×  0.0125 0.18 0.130 
 24 
Table 4. The total number of microneedles in an array for various optimum 
microneedle arrays. 
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Array Nt 
10×10 100 3×19 57 4×4 16 4×8 32 
11×11 121 4×6 24 5×5 25 5×18 90 
12×12 144 5×8 40 6×6 36 6×11 66 
13×13 169 6×16 96 7×7 49 7×19 133 
14×14 196 7×15 105 8×8 64 8×10 80 
15×15 225 8×15 120 9×9 81 9×12 108 
16×16 256 9×19 171 10×10 100 10×15 150 
17×17 289 10×13 130 11×11 121 11×15 165 
18×18 324 11×20 220 12×12 144 12×18 216 
19×19 361 12×19 228 13×13 169 13×14 182 
20×20 400 13×5 195 14×14 196 14×19 266 
   14×18 252 15×15 225 15×20 300 
   15×19 285 16×16 256 16×13 208 
   16×4 64 17×17 289 17×20 340 
   17×12 204 18×18 324 18×17 306 
   18×19 342 19×19 361 19×17 323 
   19×6 114 20×20 400 20×20 400 
   20×20 400       
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Table 5. The correlations of various microneedles patterns for both solid and hollow 
microneedles corresponding to their optimum dimensions in Table 3. 
 
Where K is the optimized skin permeability (cm/s) and D is the diffusion coefficient 
of various drugs (i.e., calcein, insulin, BSA (bovine serum albumin), nano25 and 
nano50 (nanosphere particles with radii of 25 nm and 50 nm, respectively) in skin 
(cm2/s). 
               Microneedle types 
Pattern 
Solid Hollow 
Square 0008.0D618.1K −×=  0007.0D5519.1K +×=  
Diamond 0029.0D8125.0K −×=  0003.0D776.0K +×=  
Triangular 0007.0D936.0K +×=  0014.0D8959.0K +×=  
Rectangular 0002.0D622.1K +×=  0054.0D0806.2K −×=  
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Figure 6. Influence of the aspect ratio of pitch over microneedle radius (α) of 
solid (dark markers) and hollow (blank markers) microneedles on our 
optimization function (g) for various patterns. 
List of Figures: 
 
Figure 1. The schematic diagrams (top view) of: (a) square pattern with a square 
patch microneedle array, (b) diamond/triangular pattern with a square 
patch microneedle array and (c) rectangular pattern with a rectangular 
patch microneedle array. Here R is the radius of microneedles, Pt is the 
pitch in x or y direction of square pattern, Ptn and Ptm are the pitch in x 
and y direction of diamond, triangular and rectangular pattern, 
respectively. 
 
Figure 2. The relation between optimization function (g) and the microneedle 
surface area (A) of solid (dark markers) and hollow (blank markers) 
microneedles of various patterns with their optimum values in Table 3 
for aspect ratio (α) of solid and hollow microneedles is 3.5 and 3.2, 
respectively. 
 
Figure 3. The relations between optimization function (g) and the microneedle 
radius (R) of solid (dark markers) and hollow (blank markers) 
microneedles of various patterns with their optimum values in Table 3 
for aspect ratios (α) of solid and hollow microneedles is 3.5 and 3.2, 
respectively. 
 
Figure 4. The relation between the optimization function (g) and the optimum 
total number of microneedles (Nt) in Table 4 for solid (dark markers) 
and hollow (blank markers) microneedles of various patterns for aspect 
ratio (α) of solid and hollow microneedles is 3.5 and 3.2, respectively. 
 
Figure 5. Influence of the aspect ratio of pitch over microneedle radius (α) of 
solid (dark markers) and hollow (blank markers) microneedles on the 
optimum pitch (Pt) for various patterns. 
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Figure 7. Influence of epidermis thickness (h) of solid microneedles for the 
optimum microneedles array of various patterns listed in Table 3 for 
various groups age (Artz et al., 1979) for a given anatomical region 
(i.e., medial thigh) on the optimized skin permeability (K). 
 
Figure 8. Influence of epidermis thickness (h) of solid microneedles for the 
optimum microneedles array of various patterns listed in Table 3 for 
different races (Lee and Hwang, 2002) for a given anatomical region 
(i.e., chest) on the optimized skin permeability (K). 
 
Figure 9. Influence of epidermis thickness (h) of solid microneedles for the 
optimum microneedles array of various patterns listed in Table 3 for 
different anatomical regions (Lee and Hwang, 2002) for a given sex 
(i.e., male) on the optimized skin permeability (K). 
 
Figure 10. Influence of epidermis thickness (h) of solid microneedles for the 
optimum microneedles array of various patterns listed in Table 3 for 
different sex (Lee and Hwang, 2002) for a given anatomical region 
(i.e., sole) on the optimized skin permeability (K). 
 
Figure 11. Influence of microneedle length (L) of hollow microneedles for the 
optimum microneedles array of various patterns listed in Table 3 on the 
optimized skin permeability (K). 
 
Figure 12. Influence of applying our optimization model for solid microneedles of 
the optimum microneedles listed in Table 3 on the optimized skin 
permeability (K) for different drugs (i.e., insulin is hexameric insulin, 
nano(25) and nano(50) are nanosphere particles with molecular radii of 
25 nm and 50 nm, respectively). 
 
Figure 13. Influence of applying our optimization model for hollow microneedles 
of the optimum microneedles listed in Table 3 on the optimized skin 
permeability (K) for different drugs (i.e., insulin is hexameric insulin, 
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nano(25) and nano(50) are nanosphere particles with molecular radii of 
25 nm and 50 nm, respectively). 
 
Figure 14. Relationship between the optimized skin permeability (K) and 
diffusion coefficient (D) of the optimum solid microneedles listed in 
Table 3 for various drugs (i.e., calcein, insulin, BSA (bovine serum 
albumin), nano25 and nano50 (nanosphere particles with radii of 25 
nm and 50 nm, respectively)). 
 
Figure 15. Relationship between the optimized skin permeability (K) and 
diffusion coefficient (D) of the optimum hollow microneedles listed in 
Table 3 for various drugs (i.e., calcein, insulin, BSA (bovine serum 
albumin), nano25 and nano50 (nanosphere particles with radii of 25 
nm and 50 nm, respectively)). 
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Figure 4. 
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Figure 5.
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Figure 6.  
0
0.019
0.038
0.057
0.076
0.095
0.114
0.133
0 5 10 15 20 25 30 35 40
Square Diamond
Triangular Rectangular
Square Diamond
Triangular Rectangular
0
0.003
0.006
0.009
0.012
0.015
0 10 20 30 40
Aspect ratio, α (-) 
 
O
pt
im
iz
at
io
n 
Fu
nc
tio
n,
 g
 (-
) 
 
 35 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.  
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Figure 8. 
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Figure 10. 
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Figure 11.  
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Figure 12.  
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Figure 13.  
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Figure 14.  
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Figure 15.  
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